Call us today at (803) 830 4940 to schedule a consultation or learn more about our Semaglutide program
Specifically, the total eGFR slope was 1.16 ml/min/1.73m2/year slower, the risk of major cardiovascular events was decreased by 18%, and the risk of all-cause mortality was reduced by 20%
Information and products are meant for general use only and are not intended to diagnose, cure, treat, or prevent any disease or provide medical advice
More and more medical studies are linking GLP-1 medications with serious intestinal problems like stomach paralysis
With over two decades of expertise in incretin biology and metabolic disease research at Eli Lilly, Dr
By suppressing hepatic glucose output, Semaglutide helps lower fasting blood glucose levels and contributes to better glycemic control